Xalkori Approved For Rare Genetic Form of Lung Cancer

FRIDAY, March 11, 2016 — Xalkori (crizotinib) has been approved by the U.S. Food and Drug Administration to treat advanced non-small cell lung cancer (NSCLC) with tumors that have a rare ROS-1 gene mutation.
The drug was approved in 2011 to treat…
Source: Topamax